FDA heavily criticized by independent institute over Biogen approval

Independent US research institute ICER has criticized the FDA over its recent approval, saying it believes more studies are required to alleviate "substantial" uncertainty surrounding Biogen's drug, Aduhelm.

The US Food and Drug Administration (FDA) approved Biogen's Alzheimer's drug Aduhelm on Monday, and that decision is now being criticized.

The Institute for Clinical and Economic Review (ICER) is a US-based independent research institute that evaluates the efficacy of new drugs.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs